Cyclin-dependent Kinase 5 in the Ventral Tegmental Area Regulates Depression-related Behaviors

Overview

Journal J Neurosci

Specialty Neurology

Date 2014 May 3

PMID 24790206

Citations 31

Authors

Peng Zhong

Xiaojie Liu

Zhen Zhang

Ying Hu

Sarah J Liu

Martha Lezama-Ruiz

Milan Joksimovic

Qing-Song Liu

Affiliations

Soon will be listed here.

Abstract

Dopamine neurons in the ventral tegmental area (VTA) govern reward and motivation and dysregulated dopaminergic transmission may account for anhedonia and other symptoms of depression. Cyclin-dependent kinase 5 (Cdk5) is a proline-directed serine/threonine kinase that regulates a broad range of brain functions through phosphorylation of a myriad of substrates, including tyrosine hydroxylase (TH), the rate-limiting enzyme for dopamine synthesis. We investigated whether and how Cdk5 activity in VTA dopamine neurons regulated depression-related behaviors in mice. Using the Cre/LoxP system to selectively delete Cdk5 in the VTA or in midbrain dopamine neurons in Cdk5(loxP/loxP) mice, we showed that Cdk5 loss of function in the VTA induced anxiety- and depressive-like behaviors that were associated with decreases in TH phosphorylation at Ser31 and Ser40 in the VTA and dopamine release in its target region, the nucleus accumbens. The decreased phosphorylation of TH at Ser31 was a direct effect of Cdk5 deletion, whereas decreased phosphorylation of TH at Ser40 was likely caused by impaired cAMP/protein kinase A (PKA) signaling, because Cdk5 deletion decreased cAMP and phosphorylated cAMP response element-binding protein (p-CREB) levels in the VTA. Using Designer Receptors Exclusively Activated by Designer Drugs (DREADD) technology, we showed that selectively increasing cAMP levels in VTA dopamine neurons increased phosphorylation of TH at Ser40 and CREB at Ser133 and reversed behavioral deficits induced by Cdk5 deletion. The results suggest that Cdk5 in the VTA regulates cAMP/PKA signaling, dopaminergic neurotransmission, and depression-related behaviors.

Citing Articles

Optogenetics and chemogenetics: key tools for modulating neural circuits in rodent models of depression.

Li S, Zhang J, Li J, Hu Y, Zhang M, Wang H Front Neural Circuits. 2025; 19:1516839.

PMID: 40070557 PMC: 11893610. DOI: 10.3389/fncir.2025.1516839.

CDK5: Insights into its roles in diseases.

Wang J, Zhang C, Jiang T, He Y, Wu Y, Zhou D Mol Biol Rep. 2025; 52(1):145.

PMID: 39836243 DOI: 10.1007/s11033-025-10253-4.

CB2 Agonist GW842166x Protected against 6-OHDA-Induced Anxiogenic- and Depressive-Related Behaviors in Mice.

Liu X, Yu H, Chen B, Friedman V, Mu L, Kelly T Biomedicines. 2022; 10(8).

PMID: 35892676 PMC: 9329798. DOI: 10.3390/biomedicines10081776.

Valproic Acid-Induced Anxiety and Depression Behaviors are Ameliorated in p39 Cdk5 Activator-Deficient Mice.

Takahashi M, Takasugi T, Kawakami A, Wei R, Ando K, Ohshima T Neurochem Res. 2022; 47(9):2773-2779.

PMID: 35674931 DOI: 10.1007/s11064-022-03642-9.

Revisiting the antidepressant-like effects of desipramine in male and female adult rats: sex disparities in neurochemical correlates.

Ledesma-Corvi S, Garcia-Fuster M Pharmacol Rep. 2022; 74(4):626-636.

PMID: 35653030 PMC: 9349166. DOI: 10.1007/s43440-022-00372-1.

References

Chergui K, Svenningsson P, Greengard P . Cyclin-dependent kinase 5 regulates dopaminergic and glutamatergic transmission in the striatum. Proc Natl Acad Sci U S A. 2004; 101(7):2191-6. PMC: 357074. DOI: 10.1073/pnas.0308652100. View

Schlaepfer T, Cohen M, Frick C, Kosel M, Brodesser D, Axmacher N . Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. Neuropsychopharmacology. 2007; 33(2):368-77. DOI: 10.1038/sj.npp.1301408. View

Tye K, Mirzabekov J, Warden M, Ferenczi E, Tsai H, Finkelstein J . Dopamine neurons modulate neural encoding and expression of depression-related behaviour. Nature. 2012; 493(7433):537-541. PMC: 4160519. DOI: 10.1038/nature11740. View

Barnett D, Bibb J . The role of Cdk5 in cognition and neuropsychiatric and neurological pathology. Brain Res Bull. 2010; 85(1-2):9-13. PMC: 3073157. DOI: 10.1016/j.brainresbull.2010.11.016. View

Porsolt R, Le Pichon M, JALFRE M . Depression: a new animal model sensitive to antidepressant treatments. Nature. 1977; 266(5604):730-2. DOI: 10.1038/266730a0. View

Farrell M, Pei Y, Wan Y, Yadav P, Daigle T, Urban D . A Gαs DREADD mouse for selective modulation of cAMP production in striatopallidal neurons. Neuropsychopharmacology. 2013; 38(5):854-62. PMC: 3671990. DOI: 10.1038/npp.2012.251. View

Bibb J, Chen J, Taylor J, Svenningsson P, Nishi A, Snyder G . Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5. Nature. 2001; 410(6826):376-80. DOI: 10.1038/35066591. View

Wightman R . Detection technologies. Probing cellular chemistry in biological systems with microelectrodes. Science. 2006; 311(5767):1570-4. DOI: 10.1126/science.1120027. View

Shirayama Y, Ishida H, Iwata M, Hazama G, Kawahara R, Duman R . Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. J Neurochem. 2004; 90(5):1258-68. DOI: 10.1111/j.1471-4159.2004.02589.x. View

10.

Joutsa J, Rinne J, Eskola O, Kaasinen V . Reduced striatal dopamine synthesis capacity is associated with symptoms of depression in patients with de novo unmedicated Parkinson's disease. J Parkinsons Dis. 2013; 3(3):325-9. DOI: 10.3233/JPD-130205. View

11.

Nestler E, Carlezon Jr W . The mesolimbic dopamine reward circuit in depression. Biol Psychiatry. 2006; 59(12):1151-9. DOI: 10.1016/j.biopsych.2005.09.018. View

12.

Berton O, McClung C, DiLeone R, Krishnan V, Renthal W, Russo S . Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science. 2006; 311(5762):864-8. DOI: 10.1126/science.1120972. View

13.

Park S, Nguyen M, Fischer A, Luke M, Affar E, Dieffenbach P . Par-4 links dopamine signaling and depression. Cell. 2005; 122(2):275-87. DOI: 10.1016/j.cell.2005.05.031. View

14.

Zhong P, Wang W, Pan B, Liu X, Zhang Z, Long J . Monoacylglycerol lipase inhibition blocks chronic stress-induced depressive-like behaviors via activation of mTOR signaling. Neuropsychopharmacology. 2014; 39(7):1763-76. PMC: 4023150. DOI: 10.1038/npp.2014.24. View

15.

Bibb J, Snyder G, Nishi A, Yan Z, Meijer L, Fienberg A . Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature. 1999; 402(6762):669-71. DOI: 10.1038/45251. View

16.

Nishi A, Snyder G, Greengard P . Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J Neurosci. 1997; 17(21):8147-55. PMC: 6573760. View

17.

Tomizawa K, Ohta J, Matsushita M, Moriwaki A, Li S, Takei K . Cdk5/p35 regulates neurotransmitter release through phosphorylation and downregulation of P/Q-type voltage-dependent calcium channel activity. J Neurosci. 2002; 22(7):2590-7. PMC: 6758295. DOI: 20026252. View

18.

Kansy J, Daubner S, Nishi A, Sotogaku N, Lloyd M, Nguyen C . Identification of tyrosine hydroxylase as a physiological substrate for Cdk5. J Neurochem. 2004; 91(2):374-84. PMC: 1855259. DOI: 10.1111/j.1471-4159.2004.02723.x. View

19.

Yorgason J, Espana R, Jones S . Demon voltammetry and analysis software: analysis of cocaine-induced alterations in dopamine signaling using multiple kinetic measures. J Neurosci Methods. 2011; 202(2):158-64. PMC: 3149733. DOI: 10.1016/j.jneumeth.2011.03.001. View

20.

Yu F, Zhong P, Liu X, Sun D, Gao H, Liu Q . Metabotropic glutamate receptor I (mGluR1) antagonism impairs cocaine-induced conditioned place preference via inhibition of protein synthesis. Neuropsychopharmacology. 2013; 38(7):1308-21. PMC: 3656374. DOI: 10.1038/npp.2013.29. View